Dispatch Bio has dosed the first participant in a Phase I trial aimed at evaluating its new immunotherapy, DISP-10, in advanced GI cancers.

The post First patient dosed with DISP-10 in Dispatch Bio’s cancer trial appeared first on Clinical Trials Arena.